There’s No Getting Around Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

ACAD belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Acadia Pharmaceuticals Inc is $2.46B. A total of 1.1 million shares were traded on the day, compared to an average of 1.82M shares.

In the most recent transaction, DAVIS STEPHEN sold 11,427 shares of ACAD for 16.94 per share on May 02 ’24. After the transaction, the CEO now owns 155,231 company shares. In a previous transaction on May 02 ’24, Schneyer Mark C. sold 3,503 shares at 16.94 per share. ACAD shares that EVP, CHIEF FINANCIAL OFFICER owns now total 32,053.

Among the insiders who sold shares, Teehan Brendan disposed of 3,477 shares on May 02 ’24 at a per-share price of $16.94. This resulted in the EVP, COO, HEAD OF COMMERCIAL holding 42,133 shares of ACAD after the transaction. In another insider transaction, Kihara James sold 1,326 shares at $16.94 per share on May 02 ’24. Company shares held by the PRINCIPAL ACCOUNTING OFFICER now total 14,370.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ACAD has a high of $33.99 and a low of $14.60.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $2.81, while its Total Shareholder’s Equity was $540.89M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.26.

Most Popular

Related Posts